Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer [HEALTH POLICY]

Conclusion:
First-line use of EGFRI in metastatic colorectal cancer is not cost effective at its current pricing relative to Bev.

Source: Journal of Oncology Practice - June 9, 2016 Category: Cancer & Oncology Authors: Riesco-Martinez, M. C., Berry, S. R., Ko, Y.-J., Mittmann, N., Giotis, A., Lien, K., Wong, W. W. L., Chan, K. K. W. Tags: Pharmacoeconomics, Cost of care, Chemotherapy, Cost Effectiveness, Decision Analysis Outcomes HEALTH POLICY Source Type: research